Independent reporting and analysis across technology, science, startups and invention.
The agreement would close a decade-old antitrust fight over insulin-pen patents listed in the FDA’s Orange Book. A court had already called the listings improper and exclusionary, but causation, Sanofi’s defense and damages remained unresolved.
Read story
The public Lean repository could turn mathematics’ ‘enormous theorem’ into a machine-checkable dependency graph. But the release is still self-assessed, and its strongest claim now depends on independent reproduction.
Read story
The government-owned antigen and expression tools could support tests for two major lymphatic-filariasis parasites. The opportunity is preclinical: NIH has disclosed promising sera results, not a validated diagnostic product.
Read story
A Nature paper shows coherent optical control of an individual organic molecular spin. The next test is whether NVision can deposit the material on a photonic chip without losing the properties that made the experiment work.
Read story
The AI system can now propose and prove properties for C software and Verilog hardware. Machine-checked proofs raise assurance, but only for the specifications, models and assumptions engineers actually review.
Read story
A peer-reviewed model evolves dark matter, gas, stars and radiation across a 500-megaparsec virtual cosmos. Its real value is not a prettier origin story, but predictions that telescopes can challenge.
Read story
A comparative study prepared for WIPO’s copyright committee offers no global rule for training generative AI. Instead, it identifies the decisions governments still face over permission, opt-outs, payment, transparency and cross-border remedies.
Read story
Anthropic’s public filing exposes a deliberately unusual control system: investors can buy economic exposure, while the seven founders retain majority voting power and an independent trust selects most directors. The offer size and price remain blank.
Read story
The Legal Board of Appeal revived an anonymized divisional application filed one day after its parent patent was granted, finding that applicants may rely on the EPO’s published outage safeguards. The decision is narrow, evidence-dependent and not a licence to ignore deadlines.
Read story